Cargando…

Neurocognition after prenatal levetiracetam, lamotrigine, carbamazepine or valproate exposure

OBJECTIVE: To examine neurocognitive functioning of children exposed prenatally to carbamazepine, lamotrigine, levetiracetam or valproate monotherapy. METHODS: In a prospective observational study, children aged 6 or 7 years, identified from the European Registry of Antiepileptic Drugs and Pregnancy...

Descripción completa

Detalles Bibliográficos
Autores principales: Huber-Mollema, Yfke, van Iterson, Loretta, Oort, Frans J., Lindhout, Dick, Rodenburg, Roos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7293688/
https://www.ncbi.nlm.nih.gov/pubmed/32112258
http://dx.doi.org/10.1007/s00415-020-09764-w
_version_ 1783546343055163392
author Huber-Mollema, Yfke
van Iterson, Loretta
Oort, Frans J.
Lindhout, Dick
Rodenburg, Roos
author_facet Huber-Mollema, Yfke
van Iterson, Loretta
Oort, Frans J.
Lindhout, Dick
Rodenburg, Roos
author_sort Huber-Mollema, Yfke
collection PubMed
description OBJECTIVE: To examine neurocognitive functioning of children exposed prenatally to carbamazepine, lamotrigine, levetiracetam or valproate monotherapy. METHODS: In a prospective observational study, children aged 6 or 7 years, identified from the European Registry of Antiepileptic Drugs and Pregnancy database in The Netherlands, were assessed using the Wechsler Intelligence Scale for Children and the developmental neuropsychological assessment. Maternal IQ was measured using Wechsler Adult Intelligence Scale. Assessors were blinded to drug exposures. RESULTS: One hundred and sixty-one children (one set of twins and 21 sibling pairs) of 139 mothers were included. As a group, children achieved average scores on neurocognitive outcomes. Children exposed to valproate (n = 22) performed lower on all six neurocognitive domains, especially language, than those exposed to carbamazepine (n = 32), lamotrigine (n = 82) or levetiracetam (n = 25). After controlling for maternal IQ and drug dose, the verbal IQ of valproate-exposed children was on average 9.1 points lower than those exposed to carbamazepine (95% confidence interval [CI] 1.3–17.0; p = 0.023), 10.3 lower than lamotrigine-exposed children (CI 3.4–17.3; p = 0.004) and 13.4 lower than levetiracetam-exposed children (CI 5.2–21.6; p = 0.002). No significant dose–effect was found. Virtually no significant differences were found between lamotrigine and levetiracetam or lamotrigine and carbamazepine exposed children. CONCLUSIONS: Consistent with previous research, valproate-exposed children experienced more problems compared to three other common antiepileptic drugs, while children exposed to lamotrigine, carbamazepine or levetiracetam revealed little to no problems. This illustrates the need for systematic follow-up of prenatally exposed children, to support pre-pregnancy counseling and treatment decisions in women of reproductive age. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s00415-020-09764-w) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-7293688
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-72936882020-06-16 Neurocognition after prenatal levetiracetam, lamotrigine, carbamazepine or valproate exposure Huber-Mollema, Yfke van Iterson, Loretta Oort, Frans J. Lindhout, Dick Rodenburg, Roos J Neurol Original Communication OBJECTIVE: To examine neurocognitive functioning of children exposed prenatally to carbamazepine, lamotrigine, levetiracetam or valproate monotherapy. METHODS: In a prospective observational study, children aged 6 or 7 years, identified from the European Registry of Antiepileptic Drugs and Pregnancy database in The Netherlands, were assessed using the Wechsler Intelligence Scale for Children and the developmental neuropsychological assessment. Maternal IQ was measured using Wechsler Adult Intelligence Scale. Assessors were blinded to drug exposures. RESULTS: One hundred and sixty-one children (one set of twins and 21 sibling pairs) of 139 mothers were included. As a group, children achieved average scores on neurocognitive outcomes. Children exposed to valproate (n = 22) performed lower on all six neurocognitive domains, especially language, than those exposed to carbamazepine (n = 32), lamotrigine (n = 82) or levetiracetam (n = 25). After controlling for maternal IQ and drug dose, the verbal IQ of valproate-exposed children was on average 9.1 points lower than those exposed to carbamazepine (95% confidence interval [CI] 1.3–17.0; p = 0.023), 10.3 lower than lamotrigine-exposed children (CI 3.4–17.3; p = 0.004) and 13.4 lower than levetiracetam-exposed children (CI 5.2–21.6; p = 0.002). No significant dose–effect was found. Virtually no significant differences were found between lamotrigine and levetiracetam or lamotrigine and carbamazepine exposed children. CONCLUSIONS: Consistent with previous research, valproate-exposed children experienced more problems compared to three other common antiepileptic drugs, while children exposed to lamotrigine, carbamazepine or levetiracetam revealed little to no problems. This illustrates the need for systematic follow-up of prenatally exposed children, to support pre-pregnancy counseling and treatment decisions in women of reproductive age. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s00415-020-09764-w) contains supplementary material, which is available to authorized users. Springer Berlin Heidelberg 2020-02-28 2020 /pmc/articles/PMC7293688/ /pubmed/32112258 http://dx.doi.org/10.1007/s00415-020-09764-w Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Original Communication
Huber-Mollema, Yfke
van Iterson, Loretta
Oort, Frans J.
Lindhout, Dick
Rodenburg, Roos
Neurocognition after prenatal levetiracetam, lamotrigine, carbamazepine or valproate exposure
title Neurocognition after prenatal levetiracetam, lamotrigine, carbamazepine or valproate exposure
title_full Neurocognition after prenatal levetiracetam, lamotrigine, carbamazepine or valproate exposure
title_fullStr Neurocognition after prenatal levetiracetam, lamotrigine, carbamazepine or valproate exposure
title_full_unstemmed Neurocognition after prenatal levetiracetam, lamotrigine, carbamazepine or valproate exposure
title_short Neurocognition after prenatal levetiracetam, lamotrigine, carbamazepine or valproate exposure
title_sort neurocognition after prenatal levetiracetam, lamotrigine, carbamazepine or valproate exposure
topic Original Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7293688/
https://www.ncbi.nlm.nih.gov/pubmed/32112258
http://dx.doi.org/10.1007/s00415-020-09764-w
work_keys_str_mv AT hubermollemayfke neurocognitionafterprenatallevetiracetamlamotriginecarbamazepineorvalproateexposure
AT vanitersonloretta neurocognitionafterprenatallevetiracetamlamotriginecarbamazepineorvalproateexposure
AT oortfransj neurocognitionafterprenatallevetiracetamlamotriginecarbamazepineorvalproateexposure
AT lindhoutdick neurocognitionafterprenatallevetiracetamlamotriginecarbamazepineorvalproateexposure
AT rodenburgroos neurocognitionafterprenatallevetiracetamlamotriginecarbamazepineorvalproateexposure